ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0439

Clinical Characteristics of Patients with ANCA-Associated Vasculitis with and Without Alpha-1 Antitrypsin Deficiency Alleles
Abstract Number: 0440

COVID-19 in Patients with ANCA Associated Vasculitis – Single Center Experience
Abstract Number: 0441

Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort
Abstract Number: 0442

Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Abstract Number: 0443

Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
Abstract Number: 0444

Prevalence of Frailty and Associated Factors in Patients with Vasculitis
Abstract Number: 0445

Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis
Abstract Number: 0446

The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis
Abstract Number: 0447

Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample
Abstract Number: 0448

All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Population-based Study
Abstract Number: 0449

Higher Disease Acuity at Presentation and Increased Lower Respiratory Involvement in Hispanic and Black Patients with ANCA-Associated Vasculitis
Abstract Number: 0450

Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
Abstract Number: 0451

Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study
Abstract Number: 0452

Evaluation of the 2022 ACR/EULAR Classification Criteria for ANCA-Associated Vasculitis in a Population-based Cohort from Sweden
Abstract Number: 0453

Validation of the 2022 – American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA Associated Vasculitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].